LLY catalyst calendar

ELI LILLY & Co

Upcoming catalysts
43
Cash runway
Cash generating
Cash & investments
$9072M
Phase 3 programs
46

ELI LILLY & Co is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.

The next scheduled catalyst is A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function on October 15, 2026. There are 43 upcoming events on record.

ELI LILLY & Co generates cash from operations, so a burn-based runway figure does not apply.

Across 369 concluded trials, 91% reached completion rather than being terminated or withdrawn.

Upcoming catalysts

DateEventTypePhase
October 15, 2026 A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function Trial Milestone Phase 1
October 15, 2026 A Study of Eloralintide (LY3841136) in Healthy Participants Trial Milestone Phase 1
October 15, 2026 A Study of LY4268989 (MORF 057) in Healthy Participants Trial Milestone Phase 1
October 15, 2026 A Study of LY3867070 in Healthy Participants Trial Milestone Phase 1
November 10, 2026 est. Next quarterly earnings (projected) Earnings —
November 15, 2026 A Study of LY3537031 in Overweight, Obese, and Healthy Participants Trial Milestone Phase 1
November 15, 2026 A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight Trial Milestone Phase 3
November 15, 2026 A Study of the Pharmacokinetics and Safety of LY3537031 in Participants With Normal Liver Function and With Mild, Moderate, or Severe Liver Impairment Trial Milestone Phase 1
November 15, 2026 A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin Trial Milestone Phase 2
November 15, 2026 A Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food and Fluid in the Stomach in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes Mellitus Trial Milestone Phase 1
February 15, 2027 A Study of Mirikizumab Solution (LY3074828) in Healthy Participants Trial Milestone Phase 1
March 15, 2027 A Study of LY4515100 in Healthy Participants Trial Milestone Phase 1
April 15, 2027 A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 ) Trial Milestone Phase 1
May 15, 2027 A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting Trial Milestone Phase 3
May 15, 2027 A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors Trial Milestone Phase 1
June 15, 2027 A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease Trial Milestone Phase 2
August 15, 2027 A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes Trial Milestone Phase 3
August 15, 2027 A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes Trial Milestone Phase 3
September 15, 2027 A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight Trial Milestone Phase 2
September 15, 2027 A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1 Trial Milestone Phase 3
September 15, 2027 A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY4066708 in Healthy Participants Trial Milestone Phase 1
March 15, 2028 Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight Trial Milestone Phase 3
March 15, 2028 A Study of LY4298445 in Healthy Participants and Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA) Trial Milestone Phase 1
March 15, 2028 A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes Trial Milestone Phase 3
April 15, 2028 A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity Trial Milestone Phase 3
April 15, 2028 Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study Trial Milestone Phase 3
April 15, 2028 A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma Trial Milestone Phase 2
April 15, 2028 A Study of Brenipatide in Participants With Alcohol Use Disorder Trial Milestone Phase 3
May 15, 2028 A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO) Trial Milestone Phase 4
July 15, 2028 A Study of LY4560736 in Healthy Participants and Participants With Alzheimer's Disease (AD) Trial Milestone Phase 1
July 15, 2028 A Study of Vepugratinib (LY3866288) in Adults With Non-Muscle Invasive Bladder Cancer and Upper Tract Urothelial Cancer Trial Milestone Phase 2
September 15, 2028 A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease Trial Milestone Phase 2
October 15, 2028 Gene Therapy Trial for Otoferlin Gene-mediated Hearing Loss Trial Milestone Phase 3
October 15, 2028 A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease Trial Milestone Phase 1
April 15, 2029 A Study of LY4174794 in Participants With Obesity or Overweight Who Are Otherwise Healthy Trial Milestone Phase 1
June 15, 2029 A Study of Sofe-M in Participants With Selected Advanced Solid Tumors Trial Milestone Phase 1
December 15, 2029 Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS) Trial Milestone Phase 3
December 15, 2029 A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk Trial Milestone Phase 3
March 15, 2030 A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes Trial Milestone Phase 3
May 15, 2030 A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma Trial Milestone Phase 4
July 15, 2030 A Study of LY4175408 in Participants With Advanced Cancer Trial Milestone Phase 1
July 15, 2031 A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis Trial Milestone Phase 3
July 15, 2033 Epidemiology and Biomarker Study in Alzheimer's Disease Trial Milestone Phase 3

Track LLY alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open LLY in the tracker

Recent history

DateEventTypePhase
September 22, 2026 A Study of Eltrekibart (LY3041658) in Healthy Participants Trial Milestone Phase 1
August 26, 2026 A Study of LY4064912 in Healthy Participants and With Overweight or Obesity Trial Milestone Phase 1
August 5, 2026 Quarterly results filed (8-K) Earnings —
August 3, 2026 A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis Trial Milestone Phase 2
July 21, 2026 A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight Trial Milestone Phase 3
July 13, 2026 A Study of Lepodisiran (LY3819469) in Participants With Normal, Mild, Moderate, or Severe Liver Function Trial Milestone Phase 1
July 6, 2026 A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes Trial Milestone Phase 2
July 1, 2026 A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes Trial Milestone Phase 2
June 2, 2026 A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities Trial Milestone Phase 3
May 20, 2026 8-K filed: Other event Filing —
May 13, 2026 A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis Trial Milestone Phase 3
April 30, 2026 Quarterly results filed (8-K) Earnings —
April 28, 2026 A Study of LY4005130 in Healthy Participants Trial Milestone Phase 1
April 15, 2026 A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan Trial Milestone Phase 4
April 6, 2026 A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight Trial Milestone Phase 3
March 19, 2026 A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder Trial Milestone Phase 2
February 20, 2026 A Study of LY4060874 in Healthy Participants Trial Milestone Phase 1
February 17, 2026 A Study of LY4268989 (MORF-057) in Healthy Participants Trial Milestone Phase 1
February 4, 2026 Quarterly results filed (8-K) Earnings —
January 26, 2026 A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight Trial Milestone Phase 1
January 22, 2026 Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1) Trial Milestone Phase 3
January 20, 2026 A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities Trial Milestone Phase 3
January 19, 2026 A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity Trial Milestone Phase 1
January 12, 2026 A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) Trial Milestone Phase 3
January 2, 2026 A Study to Evaluate Pharmacokinetics of LY3209590 in Pediatric Participants With Type 2 Diabetes Mellitus Trial Milestone Phase 1
December 16, 2025 A Study of LY4064809 in Healthy Adult Chinese Participants Trial Milestone Phase 1
November 21, 2025 8-K filed: Leadership change Corporate —
November 21, 2025 A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN) Trial Milestone Phase 3
November 8, 2025 A Study of Multiple Olomorasib (LY3537982) Capsules in Healthy Participants Trial Milestone Phase 1
October 30, 2025 Quarterly results filed (8-K) Earnings —

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.